Corvus' soquelitinib shows promise in oncology & autoimmune fields, with Phase 3 PTCL data as a key catalyst. Click here to ...

"We were interested in how CD73, an emerging checkpoint molecule, is regulated and how we could improve immune therapy in the context of cancer," said Zhang, who was co-senior author of the study.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

HIF-1α, trefoil factor 1 (TFF1), ecto-5-prime nucleotidase (CD73), and multi drug resistance gene 1 (MDR1) mRNA and HIF-1α protein expression were determined by real-time PCR and Western blot ...

The three assets are a pair of anti-TIGIT antibodies – domvanalimab (AB154) and AB308 – along with adenosine A2a/A2b receptor antagonist etrumadenant and small-molecule CD73 inhibitor ...

However, none of the rival programmes have advanced too far in clinical development, and a trial of one regimen – the combination of AZ's A2A drug AZD4635 and a CD73 blocking agent called ...

State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, China ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.